Baiyunshan Pharmaceutical's Unit Gets Nod for Tadalafil Tablets

MT Newswires Live

06/09

Guangzhou Baiyunshan Pharmaceutical General Factory, a unit of Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874), received drug registration certificates for Tadalafil tablets from China's National Medical Products Administration.

The drug is mainly used for the treatment of male erectile dysfunction, according to a Shanghai bourse disclosure on June 6.

The certificate is valid until May 26, 2030, the disclosure said

The Chinese pharmaceutical company invested approximately 2.5 million yuan in research and development for the 2.5-milligram specification of the drug and 4.3 million yuan for the 5-milligram specification.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542874129"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542874129\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542874129?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 12:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542874129","market":"fut","top_or_hot":-1,"title":"Baiyunshan Pharmaceutical's Unit Gets Nod for Tadalafil Tablets","media":"MT Newswires Live","content":"<html><body><p> Guangzhou Baiyunshan Pharmaceutical General Factory, a unit of Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874), received drug registration certificates for Tadalafil tablets from China's National Medical Products Administration.</p><p>The drug is mainly used for the treatment of male erectile dysfunction, according to a Shanghai bourse disclosure on June 6.</p><p>The certificate is valid until May 26, 2030, the disclosure said</p><p>The Chinese pharmaceutical company invested approximately 2.5 million yuan in research and development for the 2.5-milligram specification of the drug and 4.3 million yuan for the 5-milligram specification.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baiyunshan Pharmaceutical's Unit Gets Nod for Tadalafil Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaiyunshan Pharmaceutical's Unit Gets Nod for Tadalafil Tablets\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-06-09 12:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Guangzhou Baiyunshan Pharmaceutical General Factory, a unit of Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874), received drug registration certificates for Tadalafil tablets from China's National Medical Products Administration.</p><p>The drug is mainly used for the treatment of male erectile dysfunction, according to a Shanghai bourse disclosure on June 6.</p><p>The certificate is valid until May 26, 2030, the disclosure said</p><p>The Chinese pharmaceutical company invested approximately 2.5 million yuan in research and development for the 2.5-milligram specification of the drug and 4.3 million yuan for the 5-milligram specification.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0070","symbol_name":"員工持股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2542874129","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542874129","pubTimestamp":1749445111,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guangzhou Baiyunshan Pharmaceutical General Factory, a unit of Guangzhou Baiyunshan Pharmaceutical , received drug registration certificates for Tadalafil tablets from China's National Medical Products Administration.The drug is mainly used for the treatment of male erectile dysfunction, according to a Shanghai bourse disclosure on June 6.The certificate is valid until May 26, 2030, the disclosure saidThe Chinese pharmaceutical company invested approximately 2.5 million yuan in research and development for the 2.5-milligram specification of the drug and 4.3 million yuan for the 5-milligram specification.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0070":"员工持股","BK1606":"中医药概念","BK1515":"抗疫概念","BK0188":"融资融券","BK0012":"证金概念","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","BK0175":"白马股","BK0196":"行业龙头","BK0097":"医药电商","00874":"白云山","BK0183":"MSCI概念","BK0239":"医药制造","BK0028":"国家队","BK1197":"保健护理产品经销商","BK0096":"民营医院"},"translate_title":"白云山药业旗下他达拉非片获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":0.9,"00874":0.9},"content_text":"Guangzhou Baiyunshan Pharmaceutical General Factory, a unit of Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874), received drug registration certificates for Tadalafil tablets from China's National Medical Products Administration.The drug is mainly used for the treatment of male erectile dysfunction, according to a Shanghai bourse disclosure on June 6.The certificate is valid until May 26, 2030, the disclosure saidThe Chinese pharmaceutical company invested approximately 2.5 million yuan in research and development for the 2.5-milligram specification of the drug and 4.3 million yuan for the 5-milligram specification.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}